The PUMA Deal Is Real. The Stock Price Is the Joke.

# The PUMA Deal Is Real. The Stock Price Is the Joke.

Inter Parfums walked into the last month with two things: a brand-new, through-2037 worldwide license to turn PUMA into a fragrance empire, and a second-quarter report that made everyone at the table nervous at once. You don't get to be that polarizing without something interesting happening.

Let's start with the fun part, because it's the part everyone's talking about. On September 22, Inter Parfums (NASDAQ: IPAR) announced it now owns the exclusive rights to create, produce and distribute PUMA fragrances globally. Twelve years of it. The first scent doesn't hit shelf until 2027. That's not a catalyst for this quarter's earnings. It's a catalyst for a thesis deck, a roadshow, and a stock that already ran.

Here's the dry reality check that the bulls keep dancing around: the PUMA deal contributes essentially nothing to net income until 2027. Not next quarter. Not next year. The near-term earnings impact is nil, and the upside is inherently speculative—all the way until a product a stranger might buy proves people want it. That's a bet, not a fact.

Now the part that should actually keep you up at night. Inter Parfums reported Q2 sales of $341 million, up 2% year-over-year, right at consensus. Fine. But operating income collapsed 17% to $49 million. Operating margin compressed 330 basis points to a thin 14.4%. Gross margin slipped another 70 bps to 65.5%. Diluted EPS fell to $0.95 from $0.99. And this wasn't a one-off blip—first-half operating income dropped 8% to $123 million even as revenue climbed.

So the company is growing revenue while quietly setting fire to its margins. That's a worse problem than shrinking revenue, because growth without profitability just buys you a more expensive narrative.

And for the record, a meaningful chunk of that "2% growth" was the euro doing the heavy lifting, not demand. The dollar-euro rate moved from 1.13 to 1.16, which alone added roughly 1% to Q2 sales and 3% to the half. Strip out the currency and you're looking at a business barely moving organically, in a growth trajectory that has gone from 21% in 2023 to around 2.5% in 2025. That's not a deceleration. That's a flatline with a spreadsheet.

Let me be fair to the bulls, because they're not wrong about everything. The balance sheet is genuinely strong: $169.7 million in cash, a current ratio near 3.3, consistent free-cash-flow conversion, and returns on invested capital in the high teens. The PUMA license is real and, if executed, could be a meaningful long-term lever for a company whose whole moat is converting famous names into famous-smelling bottles. They extended the Roberto Cavalli license through 2046, locked up Coach through 2031, GUESS through 2048. Management is telling you a 2027 blockbuster cycle is coming—new launches across every brand pulling in over $100 million annually, plus Longchamp and Off-White joining the party.

But here's the thing that separates a trade from a story: Goldman Sachs says those 2027 blockbuster launches are already priced into the stock. Canaccord gave it a Buy and a $151 price target. Goldman cut it to Neutral at $129. BWS went to Sell at $85. The consensus target sits around $126.67. That is a wildly split board of analysts arguing about a single company, and the range between the bear and the bull is roughly 85%. Nobody here is confident; they're just arguing about the direction.

And the stock is paying up for the optimism. It trades around 23 times forward earnings against a profile that is neither growing fast nor stabilizing. That's not a bargain on a slowing-growth stock. That's a stock asking to be perfect and charging admission for the privilege.

On the tape, it's been bouncing around the $108-to-$116 range, caught between a weaker-than-naive technical read and a long-term uptrend it's still technically riding. Momentum is soft. The short book is crowded at nearly 11% of float—people who read the margins and decided they didn't like what they saw.

My take? Inter Parfums is a high-quality franchise running into a wall of its own making: margins that won't hold and growth that's gone currency-driven and flat. The PUMA license is a real asset, but it's a 2027 story wearing a 2026 news cycle. I'm not chasing it into the November 4 earnings print, where a margin miss against an already-elevated multiple could do exactly what the short sellers are hoping for.

The smart move here isn't to fall in love with the dream. It's to wait for a price that reflects the grind, not the pitch deck. Buy the weakness, size past the binary, and let someone else take the call on whether PUMA can sell perfume. The story's good. The price is doing the talking—and it's asking for perfection on a business that's stopped delivering it.